BioDelivery Sciences International, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

BDSI 2.95 +0.10 (3.51%)
price chart
BioDelivery Sciences Announces Health Canada Approval of BELBUCA�
RALEIGH, N.C., June 23, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Health Canada, the regulatory authority in Canada, has issued a Notice of Compliance (NOC) approving BELBUCA� (buprenorphine ...
BioDelivery Sciences (BDSI) BELBUCA Approved by Health Canada  StreetInsider.com
BioDelivery Sciences: Belbuca Transition Appears To Have Worked
The big news at the end of 2016 was BioDelivery Science's reclaiming its Belbuca product, which it had originally franchised to Endo International (NASDAQ:ENDP). At first glance, seeing a larger pharmaceutical company returning a product to its creator ...
What's in Store for BioDelivery (BDSI) this Earnings Season?  Zacks.com
Turnaround Is Underway On Near-$2 BioDelivery Sciences
BioDelivery Sciences just reported quarterly results that showed a significant turnaround is underway at this beaten-down name.
BioDelivery Sciences Reports First Quarter 2017 Financial Results and ...  PR Newswire (press release)
BioDelivery Sciences International (BDSI) Jumps: Stock Up 5%  Zacks.com
BioDelivery Sciences to Present at the Jefferies 2017 Healthcare Conference ...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine.
Will BioDelivery Sciences Leave A Bad Taste In Investors' Mouths?  Seeking Alpha
BioDelivery Sciences International, Inc.'s (BDSI) has a value of $2.20 ...  Stocks Gallery
BioDelivery Sciences (BDSI) Up 16.7% Since Earnings Report: Can It Continue?
It has been about a month since the last earnings report for BioDelivery Sciences International, Inc. BDSI . Shares have added about 16.7% in that time frame, outperforming the market.
BioDelivery Sciences Announces the Granting of Two New Patents to be Listed in ...
RALEIGH, N.C., March 31, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that two important new patents were granted extending patent protection around all three of its FDA approved products, BELBUCA� ...
BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and ...
RALEIGH, N.C., March 17, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the fourth quarter and full year ended December 31, 2016, and provided an update on recent business highlights and ...
Breaking: BioDelivery Sciences International Inc (NASDAQ:BDSI) Stock Through ...
Breaking: BioDelivery Sciences International Inc (NASDAQ:BDSI) has hit maximum technical strength -- watch the technical oscillators for momentum gaps.
BioDelivery Sciences International, Inc. (BDSI) Went Down 3.64% in the last ...  HugoPress
The Case for and Against BioDelivery Sciences International, Inc. (BDSI)  StockNewsJournal
BioDelivery Sciences: Belbuca's Progress Is Encouraging
BioDelivery Sciences (NASDAQ:BDSI) beat Q1 EPS and revenue expectations. The earnings beat by itself is not that significant since it was driven by recognition of deferred revenues related to the company's re-acquisition of Belbuca rights and the ...
BioDelivery Sciences Announces Agreement with CVS/Caremark for BELBUCA� and ...
RALEIGH, N.C., June 21, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has signed an agreement with CVS/Caremark extending access to both BELBUCA� (buprenorphine) buccal film (CIII) and ...